10 mg lyophilised (freeze-dried) · single compound
$80.00 CAD
BPC-157 is a synthetic peptide based on a protective sequence found in the stomach, widely used in tissue-repair research. Laboratory studies focus on how it influences blood-vessel formation and the healing of gut, tendon, and other soft tissue.
For laboratory and research use only - not for human consumption.
Checking the live COA archive for the newest lot documentation.
Use the verification archive to select a peptide name and review all published lot records alphabetically.
View previous lab resultsBPC-157 (short for “Body Protection Compound-157”) is a synthetic pentadecapeptide - a chain of 15 amino acids (the building blocks of proteins). Its sequence is copied from a fragment of a larger protective protein found in human gastric juice (the acidic fluid the stomach uses to protect and repair its own lining). It is unusually stable in that acidic environment, which is part of why it became a practical laboratory tool.
Almost all BPC-157 research is preclinical - done in cell cultures (in vitro) and animal models, mostly rodents. The most-studied areas are gastrointestinal protection and repair (stomach and gut injury models), soft-tissue and musculoskeletal repair (tendon, ligament, muscle, and bone, including tendon-to-bone reattachment), angiogenesis (the growth of new blood vessels), and cytoprotection (broad cell- and organ-protecting effects).
No single mechanism explains every effect seen in animals. The leading hypothesis is that BPC-157 promotes angiogenesis (new blood-vessel growth) by activating the VEGFR2 pathway - a master “build new vessels” signal - and its downstream Akt-eNOS cascade. Researchers have also examined its effect on the nitric-oxide (NO) system (which controls blood-vessel tone and healing), its apparent boosting of growth-hormone-receptor levels in tendon cells, and possible activity along the gut-brain axis (two-way signalling between the digestive system and the nervous system).
BPC-157 is not an approved medicine in any jurisdiction, and this product is supplied as a research compound only. In July 2026 a US FDA advisory committee voted 8-6-1 to recommend BPC-157 for the American 503A compounding list, having reviewed it for one use only - ulcerative colitis - and against the recommendation of the FDA's own scientific reviewers. That vote is advisory and not binding: it concerns what US compounding pharmacies may work with, it is not a drug approval, and it takes effect only if the FDA accepts it and completes formal rulemaking. BPC-157 is also prohibited in sport at all times under the WADA Prohibited List, where it has been listed since January 2022 under category S0.
A single vial containing 10 mg of BPC-157 as a lyophilised powder.
